

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Collins, *et al.*


Serial No.: Continuation of 08/846,344


Examiner: TBD

Filed: November 15, 2000

Art Unit: TBD

Title: CYTOKINE RECEPTOR CHAIN



Express Mail Label No.: EL564582449US
Date of Deposit: <u>11/15/00</u>
I hereby certify that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231

Signature <u>Julia Richie</u>
Please Print Name of Person Signing

Commissioner of Patents and Trademarks

BOX DD

Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT  
ACCOMPANYING FORM PTO-1449

Attached hereto are forms PTO-1449 and PTO 892 which list the references disclosed by Applicants during the prosecution of the predecessor applications USSN 08/609,572, filed March 1, 1996, and 08/846,344, filed April 30, 1997, from which the present application claims priority. Copies of the references which were previously submitted with the parent application are not being submitted herewith in accordance with 37 CFR 1.98(d). On the Examiner's request, Applicants will resubmit copies of any references cited in the above-identified parent application.

In accordance with the provisions of 37 C.F.R. §1.97, this statement is being filed (CHECK ONE):

- X   (1) within three (3) months of the **Filing Date** or before the mailing date of the **First Office Action** on the merits; or
- \_\_\_ (2) after the period defined in (1) but before the mailing date of a **Final Rejection** or **Notice of Allowance**, and the requisite Certification or fee under Rule 1.17(p), namely **\$240.00**, is included herein; or
- \_\_\_ (3) after the mailing date of a **Final Rejection** or **Notice of Allowance** but before the payment of the **Issue Fee**, and the requisite Certification, petition, and petition fee are included herein.

It is believed that the relevance of the cited references is apparent upon a reading of Applicants' specification; if further information is desired by the Examiner, advice of same is respectfully requested.

No representation is made hereby that these documents provide all of the art and the Examiner is presumed to conduct an independent search of the art. However, these documents do form all of the relevant art of which Applicants are presently aware. Should Applicants become aware of additional relevant art during the prosecution of this application, Applicants will bring such art to the attention of the Examiner by means of a supplemental Information Disclosure Statement.

If any fee is due with regard to this paper, Applicants hereby authorize payment of such fee from Deposit Account No. 07-1060.


Continuation of USSN 08/846,344

November 15, 2000

Page 3

Early examination and allowance of the present application are respectfully solicited.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Elizabeth A. Hurley", written over a horizontal line.

Elizabeth A. Hurley

Reg. No. 41, 859

Attorney for Applicants

617-665-8260

American Home Products Corporation

One Campus Drive

Parsippany, New Jersey 07054

Dated: 11.15.2000

GI 5268

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Collins et al.  
Serial No. : 08/609,572  
Filed : March 1, 1996  
For : CYTOKINE RECEPTOR CHAIN

Examiner:

Art Unit:

September 23, 1996  
Honorable Commissioner of  
Patents and Trademarks  
BOX DD  
Washington, D.C. 20231

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner of Patents and Trademarks, Washington, D.C. 20231, on September 23, 1996

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with the provisions of 37 C.F.R. §§ 1.56 and 1.97, Applicants herewith submit the publications and/or patents shown on the attached form PTO-1449, for consideration by the Examiner in connection with the examination of the above-identified patent application.

In accordance with the provisions of 37 C.F.R. §1.97, this statement is being filed  
(CHECK ONE):

- X   (1) within three (3) months of the **Filing Date** or before the mailing date of the **First Office Action** on the merits; or
- (2) after the period defined in (1) but before the mailing date of a **Final Rejection** or **Notice of Allowance**, and the requisite Certification or fee under Rule 1.17(p), namely **\$200.00**, is included herein; or
- (3) after the mailing date of a **Final Rejection** or **Notice of Allowance** but before the payment of the **Issue Fee**, and the requisite Certification, petition, and petition fee are included herein.

It is believed that the relevance of the cited references is apparent upon a reading of Applicants' specification; if further information is desired by the Examiner, advice of same is respectfully requested.

No representation is made hereby that these documents provide all of the art and the Examiner is presumed to conduct an independent search of the art. However, these documents do form all of the relevant art of which Applicants are presently aware. Should Applicants become aware of additional relevant art during the prosecution of this application, Applicants will bring such art to the attention of the Examiner by means of a supplemental Information Disclosure Statement.

If any fee is due with regard to this paper, Applicants hereby authorize payment of such fee from Deposit Account No. 07-1060.

Early examination and allowance of the present application are respectfully solicited.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Scott A. Brown', is written over a horizontal line.

Scott A. Brown  
Reg. No. 32,724  
Attorney for Applicants

GENETICS INSTITUTE, INC.  
LEGAL AFFAIRS  
87 CambridgePark Drive  
Cambridge, Massachusetts 02140  
(617) 498-8224